Trospium Chloride XR in Obese Female Patients With Overactive Bladder
Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This study evaluated the effectiveness of trospium chloride extended release (XR) in obese
female patients with overactive bladder (OAB). Patients received either placebo and trospium
chloride XR or placebo only. The study assessed the change from baseline in urinary
frequency, urgency, and incontinence for trospium chloride XR versus a placebo-pill. The
study was 14 weeks in duration.